Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950134-04-006239
Filing Date
2004-04-29
Accepted
2004-04-29 16:40:52
Documents
4
Period of Report
2003-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 10-K d14793a1e10vkza.htm 10-K/A 168316
2 EMPLOYMENT AGREEMENT - DAVID G. NANCE d14793a1exv10w18xdy.htm EX-10.18(D) 20317
3 CERTIFICATION OF CEO & CFO d14793a1exv31w1.htm EX-31.1 13575
4 CERTIFICATION OF CEO & CFO d14793a1exv32w1.htm EX-32.1 4354
  Complete submission text file 0000950134-04-006239.txt   208478
Mailing Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701
Business Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701 5127089310
INTROGEN THERAPEUTICS INC (Filer) CIK: 0001018710 (see all company filings)

EIN.: 742704230 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-21291 | Film No.: 04765594
SIC: 2834 Pharmaceutical Preparations